Abstract
Glioblastoma Multiforme (GMB) is the most aggressive primary brain tumor with poor survival rates and universal recurrence despite aggressive treatments. Recent research suggested that GBM has multiple glioma cell populations, some of which are organized in a stem cell hierarchical order with different stages of differention. Evidence indicated that recurrence is due to a development or persistance of a subpopulation of these tumor cells which are inherently resistant to treatment and these were defined as the glioma stem-like cells (GSC). It is hypothesized that GSC become highly malignant by accumulating mutations in oncogenic pathways. These cells present with specific surface markers which helps identify them. Targeting the surface markers as well as the signaling pathways of GSCs has been an ongoing research effort. This review focuses on summarizing the current treatment modalities used to glioblastoma treatments, evaluating their efficacy in controlling and eradicatig the GSCs, discussing the machanisms involved in GSC tumor proliferation and resistance to treatments in addition to proposing potential avenues to target GSCs in order to provide a potential cure for this cancer.
Keywords: chemotherapy, glioma stem cells, immunotherapy, malignant glioma, treatment resistance.
Anti-Cancer Agents in Medicinal Chemistry
Title:Therapeutic Targeting of Malignant Glioma
Volume: 14 Issue: 8
Author(s): Daniela Alexandru-Abrams, Martin R. Jadus, Frank P. Hsu, Apostolos Stathopoulos and Daniela A. Bota
Affiliation:
Keywords: chemotherapy, glioma stem cells, immunotherapy, malignant glioma, treatment resistance.
Abstract: Glioblastoma Multiforme (GMB) is the most aggressive primary brain tumor with poor survival rates and universal recurrence despite aggressive treatments. Recent research suggested that GBM has multiple glioma cell populations, some of which are organized in a stem cell hierarchical order with different stages of differention. Evidence indicated that recurrence is due to a development or persistance of a subpopulation of these tumor cells which are inherently resistant to treatment and these were defined as the glioma stem-like cells (GSC). It is hypothesized that GSC become highly malignant by accumulating mutations in oncogenic pathways. These cells present with specific surface markers which helps identify them. Targeting the surface markers as well as the signaling pathways of GSCs has been an ongoing research effort. This review focuses on summarizing the current treatment modalities used to glioblastoma treatments, evaluating their efficacy in controlling and eradicatig the GSCs, discussing the machanisms involved in GSC tumor proliferation and resistance to treatments in addition to proposing potential avenues to target GSCs in order to provide a potential cure for this cancer.
Export Options
About this article
Cite this article as:
Alexandru-Abrams Daniela, Jadus R. Martin, Hsu P. Frank, Stathopoulos Apostolos and Bota A. Daniela, Therapeutic Targeting of Malignant Glioma, Anti-Cancer Agents in Medicinal Chemistry 2014; 14 (8) . https://dx.doi.org/10.2174/1871520614666140825105145
DOI https://dx.doi.org/10.2174/1871520614666140825105145 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Peripheral Anionic Site of Acetylcholinesterase: Structure, Functions and Potential Role in Rational Drug Design
Current Pharmaceutical Design Targeting the AKT Pathway in Glioblastoma
Current Pharmaceutical Design Sonic Hedgehog Pathway as a Target for Therapy in Angiogenesis-Related Diseases
Current Signal Transduction Therapy Nampt/Visfatin/PBEF: A Functionally Multi-faceted Protein with a Pivotal Role in Malignant Tumors
Current Pharmaceutical Design Telomere Recombination and the ALT Pathway: A Therapeutic Perspective for Cancer
Current Pharmaceutical Design Population-based Study of Risk Polymorphisms Associated with Vascular Disorders and Dementia
Current Genomics Biomedical Application of Polymers: A Case Study of Non-CNS Drugs Becoming CNS Acting Drugs
Central Nervous System Agents in Medicinal Chemistry Editorial [ Hot Topic: Targeting Tumor Angiogenesis: An Update (Guest Editor: Girolamo Ranieri)]
Current Medicinal Chemistry Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
Current Medicinal Chemistry Application of Genetic Polymorphisms in DNA Repair in the Prediction of Cancer Susceptibility and Clinical Outcome
Current Pharmacogenomics Therapeutic Potential of Perineural Invasion, Hypoxia and Desmoplasia in Pancreatic Cancer
Current Pharmaceutical Design Symmetry Plane Detection in Brain Image Analysis: A Survey
Current Medical Imaging Small Molecule Integrin Antagonists in Cancer Therapy
Mini-Reviews in Medicinal Chemistry Mitochondria Sentencing About Cellular Life and Death: A Matter of Oxidative Stress
Current Pharmaceutical Design Synthesis of [DTPA-bis(D-ser)] Chelate (DBDSC): An Approach for the Design of SPECT Radiopharmaceuticals Based on Technetium
Current Radiopharmaceuticals Targeting Indoleamine 2,3-dioxygenase (IDO) to Counteract Tumour- Induced ImmuneDysfunction: From Biochemistry to Clinical Development
Endocrine, Metabolic & Immune Disorders - Drug Targets Application of Transcranial Color-Coded Duplex Sonography in Stroke Diagnosis
Current Medical Imaging Differential Effects of Doxazosin on Renin-Angiotensin-System- Regulating Aminopeptidase Activities in Neuroblastoma and Glioma Tumoral Cells
CNS & Neurological Disorders - Drug Targets Time Dependent Distribution of MicroRNA 144 after Intravenous Delivery
MicroRNA Uncertainty in the Translation of Preclinical Experiments to Clinical Trials. Why do Most Phase III Clinical Trials Fail?
Current Gene Therapy